SCHEMBL2428129

SCHEMBL2428129

O=C(NCc1ccc(S(=O)(=O)N2CCN(c3ccc(O)cc3)CC2)s1)c1ccc(Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 1/20 0.56
MAPK10 P53779 1/20 0.56
BCL2 P10415 1/20 0.55
BCL2L1 Q07817 1/20 0.55
SMN1; SMN2 Q16637 4/20 0.49
LMNA P02545 3/20 0.49
HTT P42858 2/20 0.49
KDM4E B2RXH2 1/20 0.49
MEN1 O00255 5/20 0.49
KMT2A Q03164 5/20 0.49
MAPT P10636 4/20 0.48
THRB P10828 1/20 0.47
POLB P06746 4/20 0.46
ALDH1A1 P00352 3/20 0.46
JAK2 O60674 1/20 0.46
RAB9A P51151 1/20 0.46
TDP1 Q9NUW8 2/20 0.45
NPSR1 Q6W5P4 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2423054 0.96 MAPK9 (0.59) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2423073 0.91 MAPK9 (0.55) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2422491 0.91 MAPT (0.58) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2424858 0.91 MAPK9 (0.61) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL4965751 0.91 SMN1; SMN2 (0.53) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2421411 0.90 MAPK9 (0.53) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2421831 0.89 MAPK9 (0.55) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2422063 0.88 MAPK9 (0.52) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2426378 0.85 MAPK9 (0.53) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2
SCHEMBL2423962 0.85 MAPK9 (0.58) MAPK9MAPK10BCL2BCL2L1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 US claimed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 US claimed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 EP claimed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 CN claimed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 CN claimed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 EP claimed
US-8658640-B2 JNK inhibitors for the treatment of endometriosis MERCK SERONO SA (CH) 2014-02-25 US disclosed
US-8592414-B2 JNK inhibitors for the treatment of endometriosis Merck Serono, S.A. (CH) 2013-11-26 US disclosed
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-24 US disclosed
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS LABORATOIRES SERONO S.A. (CH) 2013-10-10 US disclosed
US-8012995-B1 Pharmaceutically active sulfonamide derivatives MERCK SERONO SA (CH) 2011-09-06 US disclosed
US-7705052-B2 Sulfonamide derivatives for the treatment of diabetes MERCK SERONO SA (CH) 2010-04-27 US disclosed
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases LABORATOIRES SERONO SA (CH) 2009-07-09 US disclosed
CN-1960726-A Composition comprising a jnk inhibitor and cyclosporin APPLIED RESEARCH SYSTEMS (AN) 2007-05-09 CN disclosed
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) 2007-02-22 US disclosed
EP-1218374-B1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS (AN) 2005-11-16 EP disclosed
WO-2005097116-A1 COMPOSITION COMPRISING A JNK INHIBITOR AND CYCLOSPORIN APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2005-10-20 WO disclosed
CN-1189467-C Pharmaceutically active sulfonamide derivatives APPLIED RES SYSTEM ARS HOLDING (AN) 2005-02-16 CN disclosed
CN-1377347-A Pharmaceutically active sulfonamide derivatives APPLIED RESEARCH SYSTEMS (NL) 2002-10-30 CN disclosed
EP-1088821-A1 Pharmaceutically active sulfonamide derivatives Applied Research Systems ARS Holding N.V. (AN) 2001-04-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases MAPKAPK2, JUN, MAP3K13 MAPK9 33/4885MAPK10 35/4885BCL2 346/4885
US-20070043027-A1 Sulfonamide derivatives for the treatment of diabetes CBR3, INSR, CS MAPK9 2768/4885MAPK10 1940/4885BCL2 2948/4885
US-20130281447-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN MAPK9 49/4885MAPK10 40/4885BCL2 229/4885
US-20130267512-A1 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS MAPKAPK2, MAPKAPK3, JUN MAPK9 49/4885MAPK10 40/4885BCL2 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.